“This must be cancer.” That’s what I thought when I was hospitalized for a second time in two months. One month prior, I was hospitalized with diverticulitis, which was treated with strong intravenous antibiotics. Then I found myself back in the hospital. This time, it was worse than diverticulitis. I had never been so sick…
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction. The post A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine appeared first on MedCity News.
This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.
Patients expect clear information about their insurance coverage when they visit their healthcare provider, but too many leave feeling confused and financially underprepared. Experian Health’s State of Patient Access 2024 survey reveals that 56% of patients struggle to make sense of their insurance coverage without provider assistance, while 61% say improving coverage explanations is the…
“Right To Try” experimental drug program saved “thousands and thousands of lives” Former President Donald Trump on Aug. 30 Former President Donald Trump has boasted in recent months about “Right To Try,” a law he signed in 2018. It’s aimed at boosting terminally ill patients’ access to potentially lifesaving medications not yet approved by the…
On the campaign trail, both former President Donald Trump and Vice President Kamala Harris are eager to portray themselves as guardians of Medicare. Each presidential candidate accuses the other of backing spending cuts and other policies that would damage the health insurance program for older Americans. But the election’s outcome could alter the very nature…
Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design. The post Protein-Design Startup Archon Adds…
During HLTH, I spoke with some investors and digital health executives about the types of startups that they haven’t encountered yet — but would like to. The post 3 Types of Startups that Healthcare Leaders Want to See More Of appeared first on MedCity News.
In a recent interview, Elizabeth Mitchell, president and CEO of the Purchaser Business Group on Health, discussed employers’ challenges in accessing medical data, emphasizing the need for transparency and potential strategies to enhance their fiduciary responsibilities. The post PBGH CEO: Transparency is “Table Stakes” and an “Expectation” appeared first on MedCity News.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcare providers and payers. The post Redefining Clinical Development of Obesity Drugs: What Does Success Look Like? appeared first on MedCity News.